anti- GP9 antibody

Background

Glycoprotein IX Platelet (GP9), also known as CD42a, is a critical component of the glycoprotein Ib-IX-V complex, which is essential for platelet adhesion and aggregation in the hemostatic process. GP9 is a small transmembrane glycoprotein predominantly expressed on the surface of platelets and megakaryocytes. It associates with glycoprotein Ib alpha (GPIbα), glycoprotein Ib beta (GPIbβ), and glycoprotein V (GPV) to form the functional receptor complex responsible for binding von Willebrand factor (vWF) under conditions of vascular injury and high shear stress. This interaction facilitates platelet adhesion to exposed subendothelial surfaces, initiating clot formation. Mutations in the GP9 gene can lead to Bernard-Soulier syndrome, a rare autosomal recessive disorder characterized by macrothrombocytopenia and defective platelet adhesion. Due to its involvement in thrombosis and hemostasis, GP9 has been studied as a potential therapeutic target in managing thrombotic disorders and cardiovascular diseases. Additionally, its expression levels serve as a marker for platelet maturation and megakaryocyte development.